Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials 4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ
Top Ten Searches
brca1 prostate-specific antigen sclc fobt egd bmi dysplasia hematologic ovarian hccYour Article Summary
Cost-effectiveness of pioglitazone in type 2 diabetes patients with a history of macrovascular disease: a German perspective
Cost Effectiveness and Resource Allocation, 05/11/09
Scherbaum WA et al. - The findings of modelling analysis indicated that, for patients with a history of macrovascular disease, addition of pioglitazone to existing therapy reduces the long-term cumulative incidence of diabetes-complications at a cost that would be considered to represent good value for money in the German setting.
Today in Economics of Medicine...keeping you current
Receive free subspecialty "5-minute updates" via email
Medicare cracks down on false claims
Medical Economics, 11/02/09
2009 earnings survey: How do you compare
Medical Economics, 09/29/09
Higher hospital spending linked to better outcomes
American Medical News , 11/06/09
Sponsor
Article Search
Sponsor
Sponsor


See Latest Articles


